|

Insulin Therapy for Postreperfusion Hyperglycemia

RECRUITINGPhase 4Sponsored by Seoul National University Hospital
Actively Recruiting
PhasePhase 4
SponsorSeoul National University Hospital
Started2017-05-15
Est. completion2024-12-15
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03152890

Summary

Glycemic control during liver transplantation is challenging especially after reperfusion of the liver graft. Insulin dose to treat postreperfusion hyperglycemia is retrospectively analyzed using historical data. The proposed dose then is prospectively applied to the patients to assess the adequacy of the insulin dose.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Liver recipients who showed hyperglycemia (blood glucose \>180mg/dL) after reperfusion of liver graft.

Exclusion Criteria:

* pediatric patients

Conditions3

Hyperglycaemia (Diabetic)Liver DiseaseLiver Transplantation

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.